Most bought healthcare stocks in Q1 2017
See which Healthcare stocks institutional investors increased the most in Q1 2017, measured as net growth in reported share positions from Q4 2016 into Q1 2017. Notable additions at the top of this list include BRISTOL-MYERS SQUIBB CO (BMY), GRIFOLS SA-ADR (GRFS), NOVARTIS AG-SPONSORED ADR (NVS), GILEAD SCIENCES INC (GILD). These rankings aggregate SEC 13F filings from all institutional investors in our database.
Explore more:
| Symbol | Name | Net shares | Net value | New | Added | Trimmed | Sold out | Holding now |
|---|---|---|---|---|---|---|---|---|
| BMY | BRISTOL-MYERS SQUIBB CO | 12,354,512 | $572.20M | 0 | 5 | 1 | 1 | 11 |
| GRFS | GRIFOLS SA-ADR | 11,909,393 | $41.42M | 2 | 0 | 0 | 0 | 2 |
| NVS | NOVARTIS AG-SPONSORED ADR | 8,923,503 | $725.69M | 0 | 6 | 2 | 0 | 9 |
| GILD | GILEAD SCIENCES INC | 7,527,262 | $405.66M | 1 | 10 | 1 | 0 | 14 |
| BSX | BOSTON SCIENTIFIC CORP | 5,848,444 | $157.05M | 0 | 3 | 1 | 0 | 4 |
| MRK | MERCK & CO. INC. | 5,741,677 | $465.26M | 2 | 2 | 7 | 1 | 14 |
| MCK | MCKESSON CORP | 4,917,320 | $762.46M | 1 | 3 | 3 | 0 | 8 |
| TDOC | TELADOC HEALTH INC | 4,898,792 | $122.47M | 1 | 0 | 0 | 0 | 1 |
| CVS | CVS HEALTH CORP | 3,346,317 | $241.26M | 0 | 10 | 1 | 1 | 11 |
| AZN | ASTRAZENECA PLC-SPONS ADR | 3,015,482 | $299.41M | 0 | 1 | 0 | 3 | 1 |
| JNJ | JOHNSON & JOHNSON | 2,812,554 | $570.54M | 0 | 8 | 8 | 1 | 21 |
| VREX | VAREX IMAGING CORP | 2,801,283 | $94.12M | 4 | 0 | 0 | 0 | 4 |
| NVO | NOVO-NORDISK A/S-SPONS ADR | 2,464,427 | $62.42M | 0 | 2 | 0 | 0 | 2 |
| WBA | WALGREENS BOOTS ALLIANCE INC | 2,331,927 | $198.13M | 0 | 4 | 3 | 0 | 9 |
| UNH | UNITEDHEALTH GROUP INC | 1,991,151 | $422.00M | 2 | 5 | 7 | 2 | 15 |
| CAH | CARDINAL HEALTH INC | 1,776,601 | $204.22M | 1 | 4 | 1 | 1 | 7 |
| CNC | CENTENE CORP | 1,372,101 | $140.48M | 0 | 3 | 0 | 0 | 3 |
| UHS | UNIVERSAL HEALTH SERVICES-B | 1,345,565 | $175.12M | 0 | 1 | 1 | 1 | 2 |
| AMRN | AMARIN CORP PLC -ADR | 1,344,200 | $4.35M | 0 | 1 | 0 | 0 | 1 |
| LLY | ELI LILLY & CO | 1,219,969 | $143.75M | 0 | 3 | 2 | 0 | 5 |
| EW | EDWARDS LIFESCIENCES CORP | 1,182,417 | $112.34M | 1 | 1 | 1 | 0 | 3 |
| OSUR | ORASURE TECHNOLOGIES INC | 934,700 | $29.50M | 0 | 1 | 0 | 0 | 1 |
| DVA | DAVITA INC | 707,982 | $196.82M | 1 | 2 | 0 | 1 | 5 |
| NKTR | NEKTAR THERAPEUTICS | 665,600 | $15.62M | 1 | 0 | 0 | 0 | 1 |
| ABBV | ABBVIE INC | 653,520 | $49.77M | 0 | 6 | 5 | 1 | 13 |
| HUM | HUMANA INC | 643,323 | $142.32M | 1 | 1 | 2 | 0 | 4 |
| AMGN | AMGEN INC | 617,545 | $138.54M | 0 | 2 | 5 | 1 | 9 |
| ABT | ABBOTT LABORATORIES | 616,128 | $88.97M | 1 | 2 | 3 | 1 | 8 |
| TMO | THERMO FISHER SCIENTIFIC INC | 596,240 | $171.62M | 3 | 1 | 6 | 0 | 13 |
| PDCO | PATTERSON COS INC | 501,224 | $57.95M | 0 | 3 | 0 | 1 | 4 |
| OMI | OWENS & MINOR INC | 475,213 | $15.53M | 1 | 1 | 0 | 0 | 2 |
| WAT | WATERS CORP | 447,891 | $181.82M | 0 | 2 | 2 | 0 | 4 |
| CRL | CHARLES RIVER LABORATORIES | 401,884 | $75.13M | 0 | 1 | 2 | 0 | 3 |
| CPRX | CATALYST PHARMACEUTICALS INC | 382,400 | $746.00K | 1 | 0 | 0 | 0 | 1 |
| VNDA | VANDA PHARMACEUTICALS INC | 370,900 | $4.08M | 0 | 1 | 0 | 0 | 1 |
| IDXX | IDEXX LABORATORIES INC | 366,341 | $243.23M | 0 | 3 | 0 | 0 | 3 |
| GERN | GERON CORP | 361,147 | $848.00K | 1 | 0 | 0 | 0 | 2 |
| GKOS | GLAUKOS CORP | 357,200 | $32.76M | 0 | 1 | 0 | 0 | 1 |
| ALGN | ALIGN TECHNOLOGY INC | 353,153 | $185.87M | 0 | 3 | 1 | 0 | 5 |
| EXAS | EXACT SCIENCES CORP | 351,300 | $8.30M | 1 | 0 | 0 | 0 | 1 |
| CORT | CORCEPT THERAPEUTICS INC | 351,000 | $9.43M | 0 | 1 | 0 | 0 | 1 |
| ADAP | ADAPTIMMUNE THERAPEUTICS-ADR | 335,700 | $2.50M | 0 | 1 | 0 | 0 | 1 |
| CTLT | CATALENT INC | 331,370 | $9.38M | 1 | 0 | 0 | 0 | 1 |
| CMRX | CHIMERIX INC | 309,609 | $1.98M | 1 | 0 | 0 | 0 | 1 |
| NEO | NEOGENOMICS INC | 308,664 | $2.44M | 1 | 0 | 0 | 0 | 1 |
| DHR | DANAHER CORP | 288,768 | $173.85M | 1 | 3 | 4 | 0 | 10 |
| ITCI | INTRA-CELLULAR THERAPIES INC | 276,000 | $4.49M | 1 | 0 | 0 | 0 | 1 |
| DGX | QUEST DIAGNOSTICS INC | 274,790 | $29.81M | 0 | 1 | 1 | 1 | 2 |
| LXRX | LEXICON PHARMACEUTICALS INC | 261,505 | $3.75M | 1 | 0 | 0 | 0 | 1 |
| MASI | MASIMO CORP | 255,700 | $28.33M | 0 | 1 | 0 | 0 | 1 |
Frequently asked questions about Most bought healthcare stocks in Q1 2017
What are the most bought Healthcare stocks in Q1 2017?
The most bought healthcare stocks in Q1 2017 are those with the largest increase in reported share counts across institutional investors compared to Q4 2016, based on SEC 13F filings.
Which healthcare stocks did institutional investors added to the most in Q1 2017?
Among filers in this sector, net additions were largest in companies such as BRISTOL-MYERS SQUIBB CO (BMY), GRIFOLS SA-ADR (GRFS), NOVARTIS AG-SPONSORED ADR (NVS), based on aggregated 13F data.
How is institutional buying calculated?
Buying is calculated by summing the net increase in shares reported by institutional investors between two consecutive quarterly 13F snapshots (compared to Q4 2016).
Does this include all institutional owners?
Yes. These rankings aggregate SEC 13F filings from all institutional investors in our database, not only the investors we track individually.
Are these trades real-time?
No. 13F filings are reported quarterly and may be delayed by up to 45 days. The data reflects positions at the end of the reporting period, not real-time trading activity.